US Bancorp’s C4 Therapeutics CCCC Stock Holding History

US Bancorp’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$263	Buy	+79	New	+$295	﹤0.01%	4174
2025 Q3	–	Sell	-11,000	Closed	-$15.7K	–	4054
2025 Q2	$15.7K	Sell	11,000 -600	-5%	-$873	﹤0.01%	3264
2025 Q1	$18.6K	Buy	11,600 +11,544	+20,614%	+$34.4K	﹤0.01%	3201
2024 Q4	$202	Buy	56 +18	+47%	+$90	﹤0.01%	4083
2024 Q3	$217	Buy	+38	New	+$229	﹤0.01%	4009
2024 Q2	–	Sell	-39	Closed	-$319	–	3994
2024 Q1	$319	Buy	+39	New	+$302	﹤0.01%	3885
2022 Q2	–	Sell	-118	Closed	-$3K	–	4091
2022 Q1	$3K	Buy	+118	New	+$2.86K	﹤0.01%	3722

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

US Bancorp's CCCC Position: Q3 2026 in Review

US Bancorp opened a new position in C4 Therapeutics (CCCC) in Q3 2026: 79 shares worth $263. The stake represents ﹤0.01% of the portfolio and ranks #4174 among its holdings. This is a return to the name: US Bancorp previously reported a position in CCCC as recently as Q2 2025.

US Bancorp first reported a position in CCCC in Q1 2022 and has held it in 7 quarters since. The position peaked at $18.6K in Q1 2025. 38 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

US Bancorp held 79 shares of C4 Therapeutics worth $263 as of Q3 2026.
C4 Therapeutics was a new US Bancorp position in Q3 2026.
C4 Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4174 holding.
US Bancorp first reported a position in C4 Therapeutics in Q1 2022 and has held it in 7 quarters since.
US Bancorp's C4 Therapeutics position peaked at $18.6K in Q1 2025.
38 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.